Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

251 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells.
Dan S, Yamori T. Dan S, et al. Among authors: yamori t. Biochem Biophys Res Commun. 2001 Jan 26;280(3):861-7. doi: 10.1006/bbrc.2000.4231. Biochem Biophys Res Commun. 2001. PMID: 11162602
Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines.
Guo WZ, Wang Y, Umeda E, Shiina I, Dan S, Yamori T. Guo WZ, et al. Among authors: yamori t. Biol Pharm Bull. 2013;36(6):1008-16. doi: 10.1248/bpb.b13-00129. Epub 2013 Apr 9. Biol Pharm Bull. 2013. PMID: 23575219
AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy.
Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T. Ohashi Y, et al. Among authors: yamori t. J Biol Chem. 2012 Feb 3;287(6):3885-97. doi: 10.1074/jbc.M111.316125. Epub 2011 Dec 9. J Biol Chem. 2012. PMID: 22158626 Free PMC article.
ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Dan S, Okamura M, Mukai Y, Yoshimi H, Inoue Y, Hanyu A, Sakaue-Sawano A, Imamura T, Miyawaki A, Yamori T. Dan S, et al. Among authors: yamori t. Eur J Cancer. 2012 Apr;48(6):936-43. doi: 10.1016/j.ejca.2011.10.006. Epub 2011 Nov 14. Eur J Cancer. 2012. PMID: 22088482
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Kong D, Dan S, Yamazaki K, Yamori T. Kong D, et al. Among authors: yamori t. Eur J Cancer. 2010 Apr;46(6):1111-21. doi: 10.1016/j.ejca.2010.01.005. Epub 2010 Feb 1. Eur J Cancer. 2010. PMID: 20129775
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Kong D, Yamori T. Kong D, et al. Among authors: yamori t. Curr Med Chem. 2009;16(22):2839-54. doi: 10.2174/092986709788803222. Curr Med Chem. 2009. PMID: 19689267 Review.
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T. Dan S, et al. Among authors: yamori t. Biochem Biophys Res Commun. 2009 Jan 30;379(1):104-9. doi: 10.1016/j.bbrc.2008.12.015. Epub 2008 Dec 16. Biochem Biophys Res Commun. 2009. PMID: 19094964
A new evaluation method for quantifying PI3K activity by HTRF assay.
Sugita H, Dan S, Kong D, Tomida A, Yamori T. Sugita H, et al. Among authors: yamori t. Biochem Biophys Res Commun. 2008 Dec 19;377(3):941-5. doi: 10.1016/j.bbrc.2008.10.083. Epub 2008 Oct 24. Biochem Biophys Res Commun. 2008. PMID: 18952065
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Kong D, Yamori T. Kong D, et al. Among authors: yamori t. Cancer Sci. 2008 Sep;99(9):1734-40. doi: 10.1111/j.1349-7006.2008.00891.x. Epub 2008 Jul 4. Cancer Sci. 2008. PMID: 18616528 Review.
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Akashi T, Nishimura Y, Wakatabe R, Shiwa M, Yamori T. Akashi T, et al. Among authors: yamori t. Biochem Biophys Res Commun. 2007 Jan 12;352(2):514-21. doi: 10.1016/j.bbrc.2006.11.052. Epub 2006 Nov 20. Biochem Biophys Res Commun. 2007. PMID: 17137555
251 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback